2019
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Science Translational Medicine 2019, 11 PMID: 31092693, PMCID: PMC6626544, DOI: 10.1126/scitranslmed.aav4508.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBRCA1 ProteinBRCA2 ProteinCell Line, TumorDNA RepairDown-RegulationE2F4 Transcription FactorFemaleGene Expression Regulation, NeoplasticHumansMice, NudePoly(ADP-ribose) Polymerase InhibitorsQuinazolinesRad51 RecombinaseReceptors, Platelet-Derived Growth FactorTumor HypoxiaVascular Endothelial Growth Factor Receptor-2Xenograft Model Antitumor AssaysConceptsHomology-directed DNA repairDNA repairE2F transcription factor 4Protein phosphatase 2ATranscription factor 4DNA repair inhibitorsPhosphatase 2ARAD51 recombinaseTranscriptional corepressorMouse tumor xenograftsSynthetic lethalityGene expressionRB2/Mouse bone marrowGrowth factor receptor inhibitionRepair inhibitorsUnknown mechanismPlatelet-derived growth factor receptor inhibitionFactor 4Human tumorsInhibitor olaparibPARP inhibitorsMutationsCombination of cediranibCancer therapy
2008
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
Mathew P, Thall P, Wen S, Bucana C, Jones D, Horne E, Oh W, Morris M, Lee Y, Logothetis C, Lin S, Fidler I. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. British Journal Of Cancer 2008, 99: 1426-1432. PMID: 18841158, PMCID: PMC2579696, DOI: 10.1038/sj.bjc.6604706.Peer-Reviewed Original ResearchConceptsPlatelet-derived growth factor receptorPlasma platelet-derived growth factorOverall survivalProgression-FreePlatelet-derived growth factor receptor phosphorylationGrowth factor receptorPeripheral blood leukocytesProstate cancerFactor receptorPlatelet-derived growth factor receptor inhibitionInferior median overall survivalMedian progression-free survivalPlacebo-controlled randomised studyBlood leukocytesMedian overall survivalProgression-free survivalMetastatic prostate cancerInhibitor imatinib mesylateIndividual treatment armsPlasma PDGF concentrationPlatelet-derived growth factorDocetaxel efficacyDocetaxel therapyImatinib armInferior survival
2007
Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases
Mathew P, Thall P, Bucana C, Oh W, Morris M, Jones D, Johnson M, Wen S, Pagliaro L, Tannir N, Tu S, Meluch A, Smith L, Cohen L, Kim S, Troncoso P, Fidler I, Logothetis C. Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. Clinical Cancer Research 2007, 13: 5816-5824. PMID: 17908974, DOI: 10.1158/1078-0432.ccr-07-1269.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBone NeoplasmsCastrationCohort StudiesDisease-Free SurvivalDocetaxelHumansImatinib MesylateMaleMiddle AgedNeoplasm MetastasisPiperazinesPlacebosProstatic NeoplasmsPyrimidinesReceptor, Platelet-Derived Growth Factor betaReceptors, Platelet-Derived Growth FactorTaxoidsConceptsPlatelet-derived growth factor receptorPlatelet-derived growth factor receptor inhibitionCastration-resistant prostate cancerBone metastasesProstate cancerPeripheral blood leukocytesP-PDGFRProgressive castration-resistant prostate cancerSerum bone-specific alkaline phosphataseMedian time to progressionProstate cancer bone metastasisBlood leukocytesBone-specific alkaline phosphataseGrade 3 toxicityUrine N-telopeptideProgression-free survivalTime to progressionBone turnover markersImatinib-treated patientsAdverse gastrointestinal eventsSecondary end pointsCancer bone metastasisEarly clinical evidenceGrowth factor receptorTaxane chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply